Ontology highlight
ABSTRACT:
SUBMITTER: Chiu CF
PROVIDER: S-EPMC4983816 | biostudies-other | 2016 May
REPOSITORIES: biostudies-other
Chiu Ching-Feng CF Chang Yi-Wen YW Kuo Kuang-Tai KT Shen Yu-Shiuan YS Liu Chien-Ying CY Yu Yang-Hao YH Cheng Ching-Chia CC Lee Kang-Yun KY Chen Feng-Chi FC Hsu Min-Kung MK Kuo Tsang-Chih TC Ma Jui-Ti JT Su Jen-Liang JL
Proceedings of the National Academy of Sciences of the United States of America 20160418 18
Therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs, such as gefitinib or erlotinib) significantly prolongs survival time for patients with tumors harboring an activated mutation on EGFR; however, up to 40% of lung cancer patients exhibit acquired resistance to EGFR-TKIs with an unknown mechanism. FOXO3a, a transcription factor of the forkhead family, triggers apoptosis, but the mechanistic details involved in EGFR-TKI resistance and cancer stemness remain ...[more]